Sanofi and GlaxoSmithKline (GSK) have signed a letter of intent for a partnership focused on developing an adjuvanted vaccine for Covid-19.
While Sanofi and GSK are also working separately to enable vaccines for the viral infection, the latest alliance is intended to combine their respective technologies.
Related Companies

Avéma Pharma Solutions
CDMO Supporting Liquid and Solid Dose Rx Product Development and Manufacturing
Topics in this article: coronavirus microblog